Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients

Cytokinetics

Status and phase

Withdrawn

Phase 2

Conditions

Heart Failure

Treatments

Drug: Omecamtiv mecarbil

Study type

Interventional

Funder types

Industry

Identifiers

NCT01077167

20090618

Details and patient eligibility

About

The purpose of this trial is to obtain a pharmacokinetic profile (i.e. amount of drug in the blood over time) of Omecamtiv mecarbil in patients with stable heart failure.

Full description

This study was conducted by Amgen as the IND holder, with Cytokinetics as a collaborator. Due to the termination of the collaboration agreement between Amgen and Cytokinetics in May 2021 and subsequent transfer of the omecamtiv mecarbil IND from Amgen to Cytokinetics, Cytokinetics is now listed as the sponsor.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The patient has signed an Informed Consent Form/Patient Information Sheet for this study approved by the governing Institutional Review Board (IRB) or Independent Ethics Committee (IEC)
≥18 years old at the time of consent
Heart failure (HF) for ≥ 3 months and New York Heart Association class II or III at enrollment
Left ventricular ejection fraction < / = 35% by most recent echocardiogram within 3 months of enrollment. For patients with cardiac resynchronization therapy (CRT), left ventricular ejection fraction (LVEF) assessment for eligibility must be performed at least 3 months after device implantation
Treated for HF with optimal, stable pharmacological therapy. In general, optimal treatment will include a beta-blocker and an Angiotensin Converting Enzyme (ACE) inhibitor and/or an Angiotensin Receptor Blocker (ARB) at doses shown to be efficacious in Heart Failure (HF) trials, unless not tolerated. Stable medical therapy is defined as having no new HF drug class introduced 4 weeks prior to enrollment, although doses of all drugs may be adjusted throughout the trial
Considered to be an appropriate candidate for study enrollment as determined by the patient's clinical laboratory findings, vital signs and electrocardiograms (ECGs) within normal range, or if outside of the normal range not deemed clinically significant in the opinion of the Investigator
For female patients only: The patient is post-menopausal (≥ 1 year) or sterilized, or if she is of childbearing potential, she is not breastfeeding, her pregnancy test is negative, she has no intention to become pregnant during the course of the study and within 1 week following the last dose of omecamtiv mecarbil, and she is using highly effective methods of birth control. Postmenopausal female is defined as 12 continuous months of spontaneous amenorrhea confirmed by a serum follicle-stimulating hormone (FSH) result > 40mIU/mL, or at least 6 weeks postsurgical bilateral oophorectomy (with or without hysterectomy) as documented in medical history (verified with an operative note, if available)
For male patients only: Male patients agree for the duration of the study and 11 weeks after the last dose of omecamtiv mecarbil to use a condom during sexual intercourse with female partners who are of reproductive potential and to have female partners use an additional effective means of contraception (eg, diaphragm plus spermicide, or oral contraceptives) or the male subject must agree to abstain from sexual intercourse for the duration of the study and 11 weeks after the last dose of omecamtiv mecarbil.

Exclusion criteria

HF hospitalization, acute coronary syndrome, myocardial infarction, percutaneous intervention coronary revascularization, transient ischemic attack or stroke, cardiac arrhythmia within 6 weeks prior to enrollment , or major surgery including thoracic or cardiac within 8 weeks prior to enrollment
Symptoms of angina at rest or with minimal activity (Canadian Cardiovascular Society class III and IV)
Severe aortic or mitral stenosis or clinically significant valvular heart disease that might lead to surgical correction within 12 months of enrollment
Hypertrophic obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, or clinically significant congenital heart disease
Refractory, end-stage, heart failure defined as subjects who are appropriate candidates in the opinion of the investigator for ventricular assist devices, continuous inotropic therapy, or hospice care
CRT implantation within 3 months or implantable cardioverter defibrillator (ICD) within 4 weeks prior to enrollment
Likely to receive cardiac transplant within 6 months after enrollment
Recipient of any major organ transplant (eg, lung, liver, heart, bone marrow, renal)
Known to be hepatitis B surface antigen, hepatitis C virus, or human immunodeficiency virus (HIV) positive, or a known diagnosis of acquired immunodeficiency syndrome
Recent (within 3 months) history of alcohol or illicit drug abuse
Concomitant non-cardiovascular disease that is expected to reduce life expectancy to less than 1 year
Routinely scheduled outpatient intravenous (IV) infusions for HF (eg, inotropes, vasodilators [eg, nesiritide], diuretics) or routinely scheduled ultrafiltration
Subjects on digoxin therapy with a steady state plasma level (approximately 6 hours post-dose) that exceeds 1.0 ng/mL at screening
Chronic antiarrhythmic therapy, with the exception of amiodarone
Currently taking, or has taken within 14 days prior to enrollment, a potent Cytochrome P450 3A4 (CYP3A4) inhibitor
Currently taking, or has taken within 28 days prior to enrollment, a potent CYP3A4 inducer
Prior treatment with omecamtiv mecarbil
Currently enrolled in, or at least 60 days or 5 half-lives, whichever is greater, since ending participation in other investigational device or drug trial(s) or receiving other investigational agent
Systolic blood pressure > 150 mm Hg or < 80 mm Hg, or diastolic blood pressure > 95 mm Hg, assessed on two separate occasions prior to enrollment
Supine heart rate ≥ 100 beats per minute after 5 minutes of rest or an untreated symptomatic bradyarrhythmia within 1 month prior to enrollment
Troponin I at screening > upper limit of normal (ULN)
Total bilirubin ≥ 1.5 times ULN, or an Alanine transaminase (ALT) or Aspartate transaminase (AST) ≥ 3 times ULN
Estimated glomerular filtration rate (GFR) ≤ 30 ml/min/1.73 m2 calculated by the Modification of Diet in Renal Disease (MDRD) equation
In the opinion of the Investigator, a condition that compromises the ability of the subject to give written informed consent or to comply with study procedures